Genfatinib-d3, also known as Imatinib-d3, is a deuterated form of Imatinib, a tyrosine kinase inhibitor primarily used in the treatment of certain cancers, particularly chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). The deuteration in Genfatinib-d3 involves the substitution of hydrogen atoms with deuterium, which can enhance the stability and metabolic tracking of the compound in biological studies. This modification may also influence its pharmacokinetic properties, allowing for more precise studies in drug metabolism and efficacy. Genfatinib-d3 retains the core structure and mechanism of action of Imatinib, targeting the BCR-ABL fusion protein and inhibiting its activity, which is crucial for the proliferation of cancer cells. The compound is typically characterized by its molecular formula, molecular weight, and specific spectral data, which can be utilized for identification and analysis in research settings. As a research tool, Genfatinib-d3 is valuable for understanding the pharmacodynamics and pharmacokinetics of Imatinib in various biological contexts.

Genfatinib-d3 (IMatinib-d3)

1134803-18-1: Genfatinib-d3, also known as Imatinib-d3, is a deuterated form of Imatinib, a tyrosine kinase inhibitor primarily used in the treatment of certain cancers, particularly chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). The deuteration in Genfatinib-d3 involves the substitution of hydrogen atoms with deuterium, which can enhance the stability and metabolic tracking of the compound in biological studies. This modification may also influence its pharmacokinetic properties, allowing for more precise studies in drug metabolism and efficacy. Genfatinib-d3 retains the core structure and mechanism of action of Imatinib, targeting the BCR-ABL fusion protein and inhibiting its activity, which is crucial for the proliferation of cancer cells. The compound is typically characterized by its molecular formula, molecular weight, and specific spectral data, which can be utilized for identification and analysis in research settings. As a research tool, Genfatinib-d3 is valuable for understanding the pharmacodynamics and pharmacokinetics of Imatinib in various biological contexts.

Imatinib-d3 (N-methyl-d3)

<p>Applications Genfatinib-d3 (Imatinib-d3) is the labeled analogue of Genfatinib, a treatment of chronic myeloid leukemia (CML). It is a COVID19-related research product.<br>References Helmann, R., et. al.: J. Clin. Oncol., 32, 415 (2014)<br></p>

CAS 1134803-18-1

Genfatinib-d3 (IMatinib-d3)

Imatinib-d3 (N-methyl-d3)

Ref: 3U-D7407

Genfatinib-d3 (Imatinib-d3)

Ref: TR-G407007